Health Canada recently approved the first disease-modifying therapy for Alzheimer’s disease, which is a long-awaited milestone that carries significant implications for private drug plans, employers and working Canadians. “Leqembi’s approval is a turning point after two decades of no new treatment options,” said Dr. Sarah Mitchell, cognitive neurologist at Sunnybrook Health Sciences Centre and director […]
Alzheimer’s disease should be an urgent health-care priority because it robs individuals of their autonomy, dignity and quality of life and takes a mental, physical and financial toll on the individual and their families, according to Dr. Sara Mitchell, a cognitive neurologist at Sunnybrook Health Sciences Centre. Speaking during a session supported by Eisai Canada […]